Papers
List our Papers
Cancer vaccination by electro-gene-transfer.
Aurisicchio L, Mancini R, Ciliberto G. Expert Rev Vaccines. 2013 Oct;12(10):1127-37. doi: 10.1586/14760584.2013.836903. Epub 2013 Sep 25.
Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.
Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L. Hum Gene Ther. 2013 Aug;24(8):728-38. doi: 10.1089/hum.2013.112.
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D’Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G. Oncotarget. 2013 Aug;4(8):1253-65.
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.
Fattore L, Marra E, Pisanu ME, Noto A, de Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto PA, Ciliberto G. J Transl Med. 2013 Jul 27;11:180. doi: 10.1186/1479-5876-11-180.
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, Fridman A, Fabregas JC, Marshall J, Scarselli E, La Monica N, Ciliberto G, Montero AJ. J Transl Med. 2013 Mar 8;11:62. doi: 10.1186/1479-5876-11-62.